WeTrials
Recruiting

Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors

What is this study?

This study tests an experimental pill called silmitasertib along with standard chemotherapy drugs for children and young adults with solid tumors. Researchers want to find the safest and most effective dose to help fight hard-to-treat cancers.

Who can participate?

This study is for children and young adults under 30 at diagnosis who have specific cancers like neuroblastoma or Ewing sarcoma that have returned or stopped responding to past treatments. Participants must also meet certain health guidelines and not be taking certain medications like blood thinners or statins.

What will happen?

Participants will take the experimental drug silmitasertib as a pill alongside standard chemotherapy drugs. Doctors will closely monitor their safety, side effects, and how well the treatment helps fight the cancer.

Where and when?

This study is currently recruiting patients at various medical centers in locations such as Alabama, Arizona, and California. The study is actively looking for participants to help researchers learn more.

Key Points
  • 1Tests an experimental drug combined with chemotherapy.
  • 2Designed for children and young adults under 30 with specific solid tumors.
  • 3Currently recruiting patients at select locations in the United States.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
NeuroblastomaEwing SarcomaOsteosarcomaRhabdomyosarcomaLiposarcoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.